Epigenome-based cancer risk prediction: rationale, opportunities and challenges
Martin Widschwendter(Universität Innsbruck), Nora Pashayan(MRC Epidemiology Unit), Yvonne Vergouwe(Erasmus MC), Joakim Dillner(Karolinska University Hospital), Bartha Maria Knoppers(McGill University Health Centre), Yann Joly(McGill University Health Centre), Line Bjørge(Haukeland University Hospital), Frank Dudbridge(University of Cambridge), Nadia Harbeck(Breast Center), Odette Wegwarth(Max Planck Institute for Human Development), Gaby Sroczynski(UMIT - Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik), Felix G. Rebitschek(Max Planck Institute for Human Development), Andrew E. Teschendorff(Shanghai Institute of Nutrition and Health), Allison Jones(University College London), Anne-Marie Tassé(McGill University and Génome Québec Innovation Centre), Iona Evans(University College London), Ineke Bolt, Michal Zikán(Charles University), David Cibula(Charles University), Ewout W. Steyerberg(Erasmus MC), Daniel Reisel(University College London), Nicoletta Colombo(University of Milano-Bicocca), Karin Sundström(Karolinska University Hospital), Inez D. de Beaufort, Uwe Siebert(Harvard University)
Cited by 173
Related Papers
Assessing the Performance of Prediction Models
|Epidemiology|2009|4.9k
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k